Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AquaVita NextGen vs Maves

AquaVita NextGen
Graded #415

Lower grade

vs+15.5
Maves
Graded #89

Higher grade

The verdict

Maves takes it — 71.8/100 to 56.3/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +61
23
84
Dose & formulationAquaVita NextGen +10
75
65
Clinical oversightAquaVita NextGen +6
82
76
Labs & monitoringAquaVita NextGen +1
53
52
FulfillmentMaves +25
62
87
Contract termsMaves +8
47
55
AquaVita NextGen · left barMaves · right bar

The numbers

MetricAquaVita NextGenMaves
WeighScore56.3/10071.8/100
GradeCC
Scorecard rank#415#89
Semaglutide$375/mo (first-month rate, compounded)$99/mo (starting dose, first-month rate, compounded)
Tirzepatide$320/mo (starting dose, 3-month plan, compounded)Not disclosed
Coverage5 statesAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
AquaVita NextGen

Graded #415 · C

Strengths

  • Physical address in Lake Forest CA
  • Named medical director (Dr. Steve Groke)
  • Both semaglutide and tirzepatide including ODT tablets
  • Compounding disclaimer present on site

Where it loses points

  • Only 5 states (AZ, CA, FL, TX, NV)
  • No LegitScript or PCAB accreditation
  • Primarily a local medspa expanding into telehealth
  • Only a first-month semaglutide price ($375, originally $499) is published; ongoing monthly price and all tirzepatide pricing remain unpublished
Maves

Graded #89 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard